MDR Tuberculosis Treatment
- PMID: 35208510
- PMCID: PMC8878254
- DOI: 10.3390/medicina58020188
MDR Tuberculosis Treatment
Abstract
Multidrug-resistant (MDR) tuberculosis (TB), resistant to isoniazid and rifampicin, continues to be one of the most important threats to controlling the TB epidemic. Over the last few years, there have been promising pharmacological advances in the paradigm of MDR TB treatment: new and repurposed drugs have shown excellent bactericidal and sterilizing activity against Mycobacterium tuberculosis and several all-oral short regimens to treat MDR TB have shown promising results. The purpose of this comprehensive review is to summarize the most important drugs currently used to treat MDR TB, the recommended regimens to treat MDR TB, and we also summarize new insights into the treatment of patients with MDR TB.
Keywords: MDR; treatment; tuberculosis.
Conflict of interest statement
The authors have no conflict of interest to declare.
Similar articles
-
Drug susceptibility patterns of Mycobacterium tuberculosis from adults with multidrug-resistant tuberculosis and implications for a household contact preventive therapy trial.BMC Infect Dis. 2021 Feb 24;21(1):205. doi: 10.1186/s12879-021-05884-4. BMC Infect Dis. 2021. PMID: 33627075 Free PMC article.
-
Multidrug-resistant tuberculosis in Imo State, Southeast, Nigeria.Niger J Clin Pract. 2020 Aug;23(8):1172-1177. doi: 10.4103/njcp.njcp_192_19. Niger J Clin Pract. 2020. PMID: 32788498
-
Evolving rifampicin and isoniazid mono-resistance in a high multidrug-resistant and extensively drug-resistant tuberculosis region: a retrospective data analysis.BMJ Open. 2019 Nov 6;9(11):e031663. doi: 10.1136/bmjopen-2019-031663. BMJ Open. 2019. PMID: 31699736 Free PMC article.
-
Multi-drug resistant tuberculosis burden and risk factors: an update.Kathmandu Univ Med J (KUMJ). 2010 Jan-Mar;8(29):116-25. doi: 10.3126/kumj.v8i1.3234. Kathmandu Univ Med J (KUMJ). 2010. PMID: 21209520 Review.
-
The past, present and future of tuberculosis treatment.Zhejiang Da Xue Xue Bao Yi Xue Ban. 2022 Dec 25;51(6):657-668. doi: 10.3724/zdxbyxb-2022-0454. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2022. PMID: 36915970 Free PMC article. Review. English.
Cited by
-
The Biological Characteristics of Mycobacterium Phage Henu3 and the Fitness Cost Associated with Its Resistant Strains.Int J Mol Sci. 2024 Aug 27;25(17):9301. doi: 10.3390/ijms25179301. Int J Mol Sci. 2024. PMID: 39273250 Free PMC article.
-
Insight into the on/off switch that regulates expression of the MSMEG-3762/63 efflux pump in Mycobacterium smegmatis.Sci Rep. 2023 Nov 21;13(1):20332. doi: 10.1038/s41598-023-47695-4. Sci Rep. 2023. PMID: 37989843 Free PMC article.
-
Breaking barriers: The potential of nanosystems in antituberculosis therapy.Bioact Mater. 2024 May 17;39:106-134. doi: 10.1016/j.bioactmat.2024.05.013. eCollection 2024 Sep. Bioact Mater. 2024. PMID: 38783925 Free PMC article. Review.
-
Design of Experiment (DoE) Approach for Developing Inhalable PLGA Microparticles Loaded with Clofazimine for Tuberculosis Treatment.Pharmaceuticals (Basel). 2024 Jun 7;17(6):754. doi: 10.3390/ph17060754. Pharmaceuticals (Basel). 2024. PMID: 38931422 Free PMC article.
-
Multidrug-resistant tuberculosis in children: A practical update on epidemiology, diagnosis, treatment and prevention.J Clin Tuberc Other Mycobact Dis. 2024 May 1;36:100449. doi: 10.1016/j.jctube.2024.100449. eCollection 2024 Aug. J Clin Tuberc Other Mycobact Dis. 2024. PMID: 38757115 Free PMC article.
References
-
- World Health Organization . Global Tuberculosis Report 2021. World Health Organization; Geneva, Switzerland: 2021.
-
- World Health Organization Implementing the End TB Strategy. Antimicrob. Agents Chemother. 2014;58:7250–7257. - PubMed
-
- World Health Organization . WHO Treatment of Tuberculosis Guidelines. 4th ed. World Health Organization; Geneva, Switzerland: 2010.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources